Vancouver, British Columbia – TheNewswire – June 30, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to providethe following update in regards to the Clinical Trial Application (CTA) to Health Canada submitted May 17, 2020 as a treatment for Covid-19 with the target drug, Cavaltinib(TM). The Company continues to navigate the fast track CTA process with Health Canada and has now submitted the clinical trial design protocol through the proposed joint venture with BiologicPharmamedical Research. Health Canada has been in regular communication guiding the process with requests for additional documentation. An additional document is now being drafted by theCompany to meet this latest request.